1 Title: SARS-CoV-2 Omicron subvariant genomic variation associations with immune evasion in 2 Northern California: A retrospective cohort study 3 4 Authors: Joshua R. Nugent, PhD¹; Mariah S. Wood, MPH¹; Liyan Liu, MSc¹; Teal Bullick²; Jeffrey M. Schapiro, MD³; Phacharee Arunleung²; Gautham Gautham²; Shiffen Getabecha, MPH²; Christina 5 6 Morales, PhD²; Laura B. Amsden, MSW, MPH¹; Crystal A. Hsiao, MPH¹; Debra A. Wadford, PhD, MS²; 7 Stacia K. Wyman, PhD, MS⁴; Jacek Skarbinski, MD^{1,3,5,6} 8 9 Affiliations: 10 1. Division of Research, Kaiser Permanente Northern California, Oakland, CA, 94612 11 2. Viral and Rickettsial Disease Laboratory, Center for Laboratory Sciences, California Department of 12 Public Health, Richmond, California, 94804 13 3. The Permanente Medical Group, Kaiser Permanente Northern California, Oakland, CA, 94612 14 4. Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, 94720 15 5. Department of Infectious Diseases, Oakland Medical Center, Kaiser Permanente Northern California, 16 Oakland, CA, 94611 17 6. Physician Researcher Program, Kaiser Permanente Northern California, Oakland, CA, 94612 18 19 Running title: Omicron genomic variation and immune evasion 20 Word count: Abstract (249); Manuscript text (2,859) 21 22 **Corresponding author:** 23 Joshua R. Nugent 24 Kaiser Permanente Division of Research 25 4480 Hacienda Drive, Building B 26 Pleasanton, CA 94588 27 Email: joshua.r.nugent@kp.org 28 Mobile: 628-282-1934 29 30 **Author Contributions:** 31 32 Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Jeffrey M. Schapiro; Laura B. Amsden; Crystal A. Hsiao; • 33 Stacia K. Wyman; Jacek Skarbinski contributed to conceptual ideas and methodology; 34 Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Teal Bullick; Stacia K. Wyman; Jacek Skarbinski 35 contributed to formal analysis; 36 Joshua R. Nugent; Liyan Liu; Stacia K. Wyman; Jacek Skarbinski contributed to writing and original • 37 draft preparation; 38 Joshua R. Nugent; Mariah S. Wood; Liyan Liu; Teal Bullick; Jeffrey M. Schapiro; Phacharee 39 Arunleung; Gautham Gautham; Christina Morales; Laura B. Amsden; Crystal A. Hsiao; Debra A. 40 Wadford; Stacia K. Wyman; Jacek Skarbinski contributed to writing, reviewing, and editing the 41 manuscript; 42 Jacek Skarbinski; Phacharee Arunleung; Christina Morales; Debra A. Wadford supervised the work. • 43 44 Declaration of interests: All authors: No conflicts of interest identified. All authors have submitted the 45 ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant 46 to the content of the manuscript have been disclosed. 47

48 Abstract

- 49 **Background:** The possibility of association between SARS-CoV-2 genomic variation and immune evasion
- 50 is not known among persons with Omicron variant SARS-CoV-2 infection.
- 51 Methods: In a retrospective cohort, using Poisson regression adjusting for sociodemographic variables
- 52 and month of infection, we examined associations between individual non-lineage defining mutations
- and SARS-CoV-2 immunity status, defined as a) no prior recorded infection, b) not vaccinated but with at
- 54 least one prior recorded infection, c) complete primary series vaccination, and/or d) primary series
- 55 vaccination and \geq 1 booster. We identified all non-synonymous single nucleotide polymorphisms (SNPs),
- insertions and deletions in SARS-CoV-2 genomes with \geq 5% allelic frequency and population frequency of
- 57 ≥5% and ≤95%. We also examined correlations between the presence of SNPs with each other, with
- 58 subvariants, and over time.
- 59 **Results:** Seventy-nine mutations met inclusion criteria. Among 15,566 persons infected with Omicron
- 60 SARS-CoV-2, 1,825 (12%) were unvaccinated with no prior recorded infection, 360 (2%) were
- 61 unvaccinated with a recorded prior infection, 13,381 (86%) had a complete primary series vaccination,
- and 9,172 (58%) had at least one booster. After examining correlation between SNPs, 79 individual non-
- 63 lineage defining mutations were organized into 38 groups. After correction for multiple testing, no
- 64 individual SNPs or SNP groups were significantly associated with immunity status levels.
- 65 Conclusions: Genomic variation identified within SARS-CoV-2 Omicron specimens was not significantly
- 66 associated with immunity status, suggesting that contribution of non-lineage defining SNPs to immune
- 67 evasion is minimal. Larger-scale surveillance of SARS-CoV-2 genomes linked with clinical data can help
- 68 provide information to inform future vaccine development.
- 69

70 Key words: SARS-CoV-2; genomic variation; immune evasion

72 Background

73	Since its emergence, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been
74	evolving, with evidence for increased transmissibility and ability to evade existing immune responses
75	elicited by prior infection or COVID-19 vaccination. ^{1,2} Multiple mutations that increase transmission and
76	immune evasion were identified when the Delta and subsequent Omicron variants (and sub-variants)
77	emerged. However, few in-depth analyses characterizing the genomic variation within a circulating
78	variant and identifying potential mutations associated with immune evasion have been conducted. In
79	addition, during the Omicron wave, individual immunity could be due to prior infection or multiple levels
80	of vaccination, due to the availability of vaccine boosters in this timeframe, and any immune evasion
81	characteristics found among mutations could be tied to a specific type of immunity, derived from, for
82	example, prior infection, immunization dose(s), or both.
83	To address these data gaps, we conducted a retrospective cohort study of persons with nucleic-
84	acid amplification test (NAAT)-confirmed SARS-CoV-2 infection with the Omicron variant confirmed by
85	whole genome sequencing. Patients were members of a large, integrated health system that had
86	detailed epidemiologic and clinical data on all participants. The study assessed overall SARS-CoV-2
87	genetic variation over time as well as the relationship between mutations and the individual's source(s)
88	of potential COVID-19 immunity. The key assumption in this study is that after adjusting for
89	sociodemographic characteristics and timeframe, an association between mutation presence and
90	vaccine- or infection-derived immunity could imply greater immune evasion for that mutation.
91	
92	Methods

93 Setting

Kaiser Permanente Northern California (KPNC) is an integrated health system that serves over
4.5 million members in Northern and Central California and provides comprehensive preventive and

96	curative care in inpatient and outpatient settings across 266 medical offices and 21 hospitals. Members
97	receive most clinical services, including laboratory testing, outpatient, and inpatient care in KPNC
98	facilities. Members have similar sociodemographic characteristics to the population of Northern and
99	Central California. ³ SARS-CoV-2 NAAT for outpatients and hospitalized patients is conducted at a
100	regional laboratory or local hospital laboratories using various platforms and specimens are sent to the
101	California Department of Public Health (CDPH) for whole genome sequencing.
102	
103	Study design
104	We conducted a retrospective cohort study of persons with NAAT-confirmed SARS-CoV-2
105	infection and whole genome sequencing-confirmed Omicron variant infection and assessed patterns
106	among non-lineage-defining mutations as well as the association between SARS-CoV-2 genetic variation
107	and immunity source (if any). This immunity was defined by prior reported SARS-CoV-2 infection or
108	vaccination. Epidemiologic and clinical data were obtained from the KPNC Virtual Data Warehouse, a
109	common data model into which standardized data are extracted from clinical and administrative
110	databases including an integrated electronic health record database (Epic, Verona, WI, USA), and from
111	other sources. ^{4,5} The study was approved by the KPNC and University of California, Berkeley Institutional
112	Review Boards with waivers of the requirement for informed consent. This activity was reviewed by the
113	Centers for Disease Control and Prevention (CDC) and conducted consistent with applicable federal law
114	and CDC policy (see e.g., 45 C.F.R. part 46.102(I)(2), 21 C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a;
115	44 U.S.C. §3501 et seq.).
116	
117	Inclusion criteria
118	We included all persons with an incident NAAT-confirmed SARS-CoV-2 infection and whole
119	genome sequencing-confirmed Omicron variant infection from January 1, 2022 to October 31, 2022 who

120 met the following criteria: 1) KPNC membership for at least one year prior to SARS-CoV-2 diagnosis; 2) 121 aged \geq 5 years and <90 years; 3) no prior receipt of COVID-19 vaccine or the completion of a primary 122 COVID-19 vaccine series of two doses of BNT162b2 [Pfizer/BioNTech] or m-RNA-1973 [Moderna/National Institutes of Health] or one dose of Ad.26.COV2.s [Janssen] more than 14 days prior 123 124 to index date; 4) incident infection defined as the first NAAT-confirmed SARS-CoV-2 infection during the 125 study period. The index date was defined as the date of NAAT-confirmation of SARS-CoV-2 infection. 126 127 SARS-CoV-2 whole genome sequencing and processing 128 KPNC is a partner in COVIDNet with CDPH and submits a majority of NAAT-confirmed SARS-CoV-129 2 specimens to COVIDNet for genomic surveillance; a subset of specimens undergo whole genome sequencing at CDPH or affiliated laboratories based on CDPH priorities, including prioritizing hospitalized 130 131 cases and a convenience sample of the first specimens received per week (number varies by burden).⁶ 132 COVIDNet consists of a set of (primarily University of California-affiliated) laboratories tapped to assist 133 CDPH because they had surplus sequencing capacity. Illumina sequencing was used by most of the sites, 134 with about 10% of genomes being sequenced by Oxford Nanopore. For this study, we only included 135 Illumina-sequenced genomes because the error rate of Nanopore is too high to accurately identify low-136 frequency mutations. Varying sets of primers were used by different institutions, but the most common 137 for the Omicron genomes were the ARTICv3 and ARTICv4 primers. The University of California, San

138Francisco lab used their own custom set of primers with more primers and shorter amplicons. After

139 sequencing, the CDPH Viral and Rickettsial Disease Laboratory links lineage information with patient

140 identifiers and shares the results with KPNC. The raw sequence files are shared with the University of

141 California, Berkeley (UCB); KPNC and UCB collaborate further to link demographic, clinical, and

142 epidemiologic data from KPNC with subsequent sequence analysis data from UCB.

The raw sequencing data were processed through a SARS-CoV-2 analysis pipeline that was 143 144 modified for this work as follows. Adapter removal and trimming were performed using bbduk 145 (http://sourceforge.net/projects/bbmap/). The reads were then aligned to the Wuhan reference 146 genome (GISAID ID: EPI ISL 402125, GenBank accession number MN908947) using minimap2⁷ followed 147 by primer trimming using iVar.⁸ Samtools was used to create a pileup file from which a consensus 148 sequence was generated. This consensus genome was created with iVar using a minimum depth of 10 149 reads and majority rule for base calling. We next used iVar to call variants from the pileup file where we 150 set the sensitivity threshold for calling a mutation to 2%. This process calls mutations for any loci where 151 at least 2% of the reads are non-reference. Using this very low threshold allowed us to capture even 152 very low frequency mutations in the sequencing data. This threshold resulted in many spurious 153 mutations from sequencing and alignment errors and therefore we later set a threshold of 5% when 154 processing mutations. This original list of variants was then annotated with the gene and amino acid 155 change (if there was one) or insertion or deletion. 156 After calling with iVar using a low-frequency threshold, mutations were compiled into a master 157 frequency matrix listing all mutations that appeared in any genome in rows, and all the genomes that each mutation appeared in columns (https://github.com/staciawyman/SC2_GenVar). The cell values 158 159 were frequency of the alternate reads at the location. A mutation had to have an allele frequency of at 160 least 5% to be included to rule out sequencing errors. This matrix was partitioned into variant-specific 161 parts to facilitate analysis. We constructed an Omicron matrix including all individuals that had the 162 Omicron lineage⁹ between January 1, 2022 and October 31, 2022 including non-synonymous SNPs, 163 insertions and deletions (indels). Pipeline code is available at https://github.com/staciawyman/SC2_GenVar. 164 165

166 *Outcome measure*

167	The primary outcome measure was, among persons with an incident NAAT-confirmed SARS-
168	CoV-2 infection, the presence of individual mutations (nonsynonymous SNPs, insertions and deletions)
169	with ≥5% allelic frequency and ≥5% and ≤95% population frequency, as well as mutation groups created
170	by grouping SNPs with a pairwise Pearson correlation coefficient > 0.7. Additionally, patterns in the
171	prevalence of these mutations were assessed as follows: as noted earlier, pairwise Pearson correlations
172	with other mutations in each infection; presence within Omicron subvariant (BA.1, BA.2, BA.4, BA.5,
173	BCD, BE, BF, Bdot), and prevalence over time.
174	
175	Primary exposure: SARS-CoV-2 immunity status
176	The primary exposure of interest in this analysis was immunity level, defined in mutually
177	exclusive categories: i) no recorded vaccination or recorded prior infection; ii) recorded prior infection
178	but no recorded vaccination; and iii) recorded vaccination (primary series complete and/or more than
179	primary series), regardless of prior infection status.
180	
181	Statistical analysis
182	Adjusted relative prevalence, shown as an adjusted rate ratio (aRR), and 95% confidence
183	intervals (CIs) for the estimates for our exposure and adjustment variables were obtained from modified

184 Poisson regression models with robust standard errors using PROC GENMOD with a log link function in

185 SAS (Version 9.4, Cary, North Carolina); statistical significance was defined as a p-value <0.05. All p-

values were adjusted for multiple comparisons to control the false discovery rate at 5%, using the

187 Benjamini-Hochberg procedure.¹⁰ To adjust for confounding, all models included age category, sex,

race/ethnicity, Charlson comorbidity index score¹¹, and index month. Adjusting for these demographic

and clinical factors accounted for differential vaccination status of these subgroups, increasing

190 vaccination rates over time, and the inherent uncertainty as to where in a population a new mutation 191 might arise. 192 193 Data Availability 194 De-identified data that underlie the results reported in this article will be made available upon 195 reasonable request. 196 197 Role of funding source The funders had no role in study design, data collection, data analysis, interpretation, or writing 198 199 of the report. 200 201 Results 202 From January 1, 2022 to October 31, 2022, 312,249 SARS-CoV-2-positive specimens were 203 submitted for sequencing, 18,603 (6.0%) underwent sequencing (Supplemental Figure 1), and 18,476 204 (5.9%) had reported lineages consistent with the Omicron variant. After applying selection criteria, 205 15,556 persons with SARS-CoV-2 Omicron variant infection were included in the analysis: 9,172 (58%) 206 vaccinated with a booster; 4,209 (26%) vaccinated with a complete primary series [two doses of Pfizer or 207 Moderna vaccine]; and 2,185 (14%) with no vaccination (Supplemental Figure 1). The prevalence of 208 Omicron subvariants in our specimens, aggregated to the week level, showed increasing diversity over 209 time (Figure 1). 210 After applying selection criteria to the sequences, we identified 78 non-lineage defining 211 mutations (all non-synonymous SNPs) in 1,456 SARS-CoV-2 SNPs included in this analysis, shown in 212 Supplemental Figure 2. Identified mutations were in the spike gene (n=44), nucleocapsid gene (n=8) 213 open reading frame 1a (ORF1a) (n=19), ORF1b (n=4), ORF3a (n=1), ORF6c (n=1), ORF10 (n=1). The

214 population frequency within our genomes of individual identified mutations ranged from 5.0% to 95.0% 215 and 46 out of 79 (58.2%) mutations were present in <50% of the overall population. Although we called 216 low-frequency mutations with our pipeline, none of them met the criteria for inclusion in our analysis. 217 Of the 78 identified SNPs that met our inclusion criteria, many co-occurred on the same 218 specimens. Supplemental Figure 2 shows the pairwise correlations of SNP presence in our dataset. Given 219 the strong pairwise correlations observed, we formed groups of SNPs that had a pairwise Pearson 220 correlation > .7, reducing the dimension to 33 SNPs/SNP groups, also shown in Supplemental Figure 2. 221 These mutation groups are largely monophyletic and segregate together across the phylogeny of 222 Omicron genomes (Supplemental Figure 3). 223 The demographics of persons with SARS-CoV-2 infection included in this analysis, stratified by 224 vaccination and prior infection status, are shown in Table 1, and the number of total reported infections 225 and those sequenced over time is shown in Supplemental Figure 4. Significant differences were found 226 between groups, thus supporting their inclusion in our covariate adjustment set. Figure 2 details some 227 of the relationships between SNP groups, time, and subvariant among the specimens in our data set. 228 While certain mutations/groups appear essentially only in a single subvariant (for example, 99.1% of 229 S:H69L mutations appear in specimens classified as BA.1 in Figure 2c), the majority of mutations/groups 230 appear in many subvariants, suggesting that they are not simply proxy measures of subvariant. Further, 231 the presence of mutations/groups do not follow clear temporal patterns (Figure 2b). While some 232 mutations such as Group 12 arise, become plentiful, then wane, others disappear and re-appear over 233 time without a clear pattern (for example, S:D1259H). Smoothed over time, grouped SNP prevalence by 234 month is shown in Supplemental Figure 5. 235 Using modified Poisson regression models with robust standard errors, we found several of our 236 33 SNP groupings (Table 2) and/or 78 individual mutations (Supplemental Table 1) that were

significantly associated with immunity status; however, after correcting p-values to adjust for multiple

238	comparisons, none of the associations were statistically significant. These findings were not
239	meaningfully changed when people with a booster vaccine were/were not aggregated with the
240	complete primary series group (Supplemental Table 2, Supplemental Table 3). The SNPs/groups with the
241	largest absolute associations with vaccination (Table 2) included some that were strongly associated
242	with a single variant (for example, ORF10:L37F, which occurred almost exclusively in BA.5 subvariants)
243	as well as some that frequently appeared in multiple variants (for example, ORF1b:N498I and group 45).
244	When looking at the evolutionary relationships with the genomes colored by vaccination status
245	(Supplemental Figure 6), vaccination status did not show a correlation with a clade/subvariant or
246	distance from the root (number of mutations with respect to the reference SARS-CoV-2 genome).
247	
248	Discussion
249	Characterizing the continuing evolution of SARS-CoV-2, along with active surveillance of
250	infections, is critical to targeting public health measures and vaccine development. Large-scale global
251	whole genome sequencing efforts have contributed substantially to our understanding of the genetic
252	variation of SARS-CoV-2 and its associations with transmissibility and immune evasion. Our current study
253	adds to this evidence base by assessing within-variant (Omicron) variation in the genome beyond the
254	already-identified subvariants such as BA.1 and BA.2 using a unique whole genome surveillance system
255	linking genomic data with detailed data on demographic, clinical and epidemiologic characteristics in a
256	well-defined population.
257	Understanding the potential for immune evasion based on mutations beyond the spike protein
258	is critical for vaccine development and understanding the mechanisms of the human immune response.
259	In this detailed analysis of genomic variation within the Omicron variant over a 10-month period in
260	California, we identified only 78 mutations that met our inclusion criteria among 15,566 genomes. These
261	mutations occurred across the entire genome, not just in the spike protein. Spike protein mutations

previously implicated with immune evasion were excluded based on population frequency. We
encourage future research to examine the entire viral genome for potential immune evasion or
increased replication or infectivity.

Our results showed that there appear to be some mutations that are tightly grouped with certain subvariants, while a number of other mutations appear across multiple subvariants. While we did not find evidence for immune evasion among our identified mutations/groups after correction for multiple testing, it is possible that we are underpowered to detect small effects over a short time period.¹² Many of the SNPs with the highest adjusted risk ratios appeared in a small number of specimens (Supplemental Table 1). While one would expect more variability from the smallest table cells if we were simply observing statistical noise, it is also possible that a larger sample could confirm these

272 stronger adjusted risk ratios.

273 Our analysis has several limitations. First, not all possible demographic and clinical variables 274 were included in our models, and if those variables are associated with immunity status and SNP 275 presence, unmeasured confounding could bias our analysis. Second, there is a risk of misclassification of 276 immunity status; though the KPNC surveillance system for vaccination is quite robust, prior infections 277 (say, diagnosed by a home test) may have gone unreported. Third, we focused on a set of specimens 278 from Northern and Central California, limiting the generalizability of our findings to this context. Finally, 279 there may be hidden bias as to which specimens were successfully sequenced based on the nucleic acid 280 viral load in the specimen (e.g., specimens with lower viral loads might not be successfully sequenced and thus would have been excluded from this analysis). Fourth, although our surveillance system has a 281 282 very robust system for assessing individual-level vaccination status, there is a small risk of 283 misclassification of persons as having incorrect immunity status.

As part of the global effort to conduct near real-time genomic surveillance for SARS-CoV-2, there has been tremendous progress in developing national genomic surveillance systems with nearly real-

286 time public reporting of circulating SARS-CoV-2 variants and uploading of consensus sequence data to publicly available genomic databases.^{13 14 15 16} However, these efforts can be improved. First, enhancing 287 288 methods to define consensus sequences to also assess for minor variation with <50% allelic frequency 289 would better define the true genomic variation of circulating SARS-CoV-2, including capturing within-290 host genetic diversity.^{17,18} Second, current SARS-CoV-2 genomic surveillance systems in the United 291 States have limited metadata on human demographics, clinical factors, epidemiologic factors, and 292 immunity status (e.g. COVID-19 vaccination and documented prior infection), particularly when compared to the United Kingdom.¹⁹ This limits the ability to correlate noted patterns in SARS-CoV-2 293 294 genetic variation and real-world clinical and epidemiologic outcomes in the United States. We present one potential analysis that uses this data linkage to better understand how SARS-CoV-2 genetic variation 295 296 might be associated with human disease, in this case evidence for immune evasion associated with 297 specific mutation clusters. Improving the clinical metadata associated with SARS-CoV-2 genomic data 298 should be a priority as we continue to improve and expand genomic surveillance. We have 299 demonstrated this capability through partnership and collaboration between a large healthcare system 300 and a state public health department, namely KPNC and CDPH/COVIDNet. 301 In summary, we demonstrate that linking SARS-CoV-2 genomic sequence data with detailed 302 clinical data revealed no significant associations between genetic variation among Omicron SARS-CoV-2 303 mutations and immunity status. Further research using larger sample sets that link SARS-CoV-2 genetic 304 data with clinical data is warranted for the potential to reveal whether SARS-CoV-2 non-lineage defining 305 genetic variation might contribute to the fitness of SARS-CoV-2 by either immune evasion or other 306 mechanism.

308	Funding Statement: This study was supported by the Rockefeller Foundation (SKW, JS), National Cancer
309	Institute of the National Institutes of Health under Award Number U01CA260584 as part of the
310	Serological Sciences Network (SeroNet) (JS), the Physician Researcher Program of The Permanente
311	Medical Group Delivery Science and Applied Research Program (JS), The Packard Foundation (SKW), and
312	The Sergey Brin Family Foundation (SKW). CDPH/COVIDNet genomic surveillance work was funded by
313	Centers for Disease Control and Prevention, Epidemiology and Laboratory Capacity for Infectious
314	Diseases, Cooperative Agreement Number 5 NU50CK000539.
315	
316	Declaration of interests: All authors: No conflicts of interest identified. All authors have submitted the
317	ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant
318	to the content of the manuscript have been disclosed.
319	
320	Acknowledgments: The authors are grateful to all Kaiser Permanente members without whom this
321	study would not have been possible. In addition, we wish to acknowledge our partnership with the
322	California Department of Public Health and participation in the California SARS-CoV-2 Whole Genome
323	Sequencing Initiative (COVIDNet). We thank the VRDL and COVIDNet Teams: Summer Adams, Allison
324	Bailey, Matt Bacinskas, Nikki Baumrind, Elizabeth Baylis, John Bell, Ricardo Berumen III, Yocelyn Cruz,
325	Mojgan Deldari, Alex Espinosa, Sabrina Gilliam, Madeline Glenn, Bianca Gonzaga, Melanie Greengard, Jill
326	Hacker, Kim Hansard, Monica Haw, Thalia Huynh, Chantha Kath, Ruth Lopez, Sharon Messenger, Alexa
327	Quintana, Chris Preas, Clarence Reyes, Maria Salas, Hilary Tamnanchit, Serena Ting, Kathy Jacobson, MD,
328	and Carol Glaser, MD.
329	
330	Data sharing statement: De-identified data that underlie the results reported in this article will be made

331 available upon reasonable request.

332

- 333 **Disclaimer:** The content is solely the responsibility of the authors and does not represent the official
- 334 views or opinions of the National Institutes of Health, Kaiser Permanente, California Department of
- 335 Public Health or the California Health and Human Services Agency.

336

- ***Additional Disclaimer:** Use of trade names and commercial sources is for identification only and does
- not imply endorsement by the California Department of Public Health or the California Health and
- Human Services Agency.

341 References

- 1. Lou F, Li M, Pang Z, et al. Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and
- 343 Immune Escape. *Front Immunol*. 2021;12. Accessed November 13, 2023.
- 344 https://www.frontiersin.org/articles/10.3389/fimmu.2021.744242
- 2. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune
- 346 escape. *Nat Rev Microbiol*. 2021;19(7):409-424. doi:10.1038/s41579-021-00573-0
- 347 3. Davis AC, Voelkel JL, Remmers CL, Adams JL, McGlynn EA. Comparing Kaiser Permanente Members
- to the General Population: Implications for Generalizability of Research. *Perm J.* 2023;27(2):87-98.
- 349 doi:10.7812/TPP/22.172
- 4. Ross TR, Ng D, Brown JS, et al. The HMO Research Network Virtual Data Warehouse: A Public Data
- 351 Model to Support Collaboration. *EGEMS Wash DC*. 2014;2(1):1049. doi:10.13063/2327-9214.1049
- 352 5. Weeks J, Pardee R. Learning to Share Health Care Data: A Brief Timeline of Influential Common Data
- 353 Models and Distributed Health Data Networks in U.S. Health Care Research. *EGEMS Wash DC*.
- 354 2019;7(1):4. doi:10.5334/egems.279
- 355 6. Wadford DA, Baumrind N, Baylis EF, et al. Implementation of California COVIDNet a multi-sector
- 356 collaboration for statewide SARS-CoV-2 genomic surveillance. *Front Public Health*. 2023;11.
- 357 Accessed November 26, 2023. https://www.frontiersin.org/articles/10.3389/fpubh.2023.1249614
- 358 7. Li H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinforma Oxf Engl.*
- 359 2018;34(18):3094-3100. doi:10.1093/bioinformatics/bty191
- 360 8. Grubaugh ND, Gangavarapu K, Quick J, et al. An amplicon-based sequencing framework for
- accurately measuring intrahost virus diversity using PrimalSeq and iVar. *Genome Biol*. 2019;20(1):8.
- 362 doi:10.1186/s13059-018-1618-7
- 363 9. O'Toole Á, Scher E, Underwood A, et al. Assignment of epidemiological lineages in an emerging
- 364 pandemic using the pangolin tool. *Virus Evol*. 2021;7(2):veab064. doi:10.1093/ve/veab064

- 365 10. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to
- 366 Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289-300. doi:10.1111/j.2517-
- 367 6161.1995.tb02031.x
- 368 11. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity
- in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383.
- 370 doi:10.1016/0021-9681(87)90171-8
- 12. Volz E. Fitness, growth and transmissibility of SARS-CoV-2 genetic variants. *Nat Rev Genet*.
- 372 2023;24(10):724-734. doi:10.1038/s41576-023-00610-z
- 13. Chen Z, Azman AS, Chen X, et al. Global landscape of SARS-CoV-2 genomic surveillance and data
- 374 sharing. Nat Genet. 2022;54(4):499-507. doi:10.1038/s41588-022-01033-y
- 14. World Health Organization. Guidance for Surveillance of SARS-CoV-2 Variants: Interim Guidance, 9
- 376 *August 2021*. World Health Organization; 2021. https://apps.who.int/iris/handle/10665/343775
- 15. Lambrou AS. Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2)
- and Omicron (B.1.1.529) Variants United States, June 2021–January 2022. MMWR Morb Mortal
- 379 *Wkly Rep*. 2022;71. doi:10.15585/mmwr.mm7106a4
- 16. Robishaw JD, Alter SM, Solano JJ, et al. Genomic surveillance to combat COVID-19: challenges and
- 381 opportunities. *Lancet Microbe*. 2021;2(9):e481-e484. doi:10.1016/S2666-5247(21)00121-X
- 382 17. Tonkin-Hill G, Martincorena I, Amato R, et al. Patterns of within-host genetic diversity in SARS-CoV-
- 383 2. Neher RA, Sawyer SL, Neher RA, Lauring AS, eds. *eLife*. 2021;10:e66857. doi:10.7554/eLife.66857
- 18. Gao R, Zu W, Liu Y, et al. Quasispecies of SARS-CoV-2 revealed by single nucleotide polymorphisms
- 385 (SNPs) analysis. *Virulence*. 2021;12(1):1209-1226. doi:10.1080/21505594.2021.1911477
- 386 19. Nicholls SM, Poplawski R, Bull MJ, et al. CLIMB-COVID: continuous integration supporting
- decentralised sequencing for SARS-CoV-2 genomic surveillance. *Genome Biol.* 2021;22(1):196.
- 388 doi:10.1186/s13059-021-02395-y
- 389

Figure 1. SARS-CoV-2-positive specimens tested by Kaiser Permanente Northern California, proportion by subvariant, by week from January 1, 2022 to October 31, 2022



Calendar time by week, January 2022 to October 2022



Figure 2: SNP/group prevalence by subvariant and week in 2022

- (A) Proportion of specimens in each sublineage by week
- (B) Proportion of specimens with a given SNP/group by week
- (C) Proportion of subvariant by SNP/group (rows sum to 100%)

Table 1: Demographics of persons included in this analysis with SARS-CoV-2 infection with Omicron variant in
Northern California stratified by vaccination/infection status, January 1, 2022 - October 31, 2022

		Not vaccinated,	Not vaccinated,		
		no prior reported	prior reported	Vaccinated	
	All	infection	infection		
Characteristic	n (%)	n (%)	n (%)	n (%)	p-value ¹
Total	15,566 (100%)	1,825 (11.7%)	360 (2.3%)	13,381 (86.0%)	
Median age in years (Interquartile range)	43.0 (30.0, 57.0)	32.0 (13.0, 49.0)	32.0 (19.0, 43.0)	44.0 (32.0, 58.0)	< 0.0001
Age in years					<0.0001
5-19	2,019 (13.0%)	594 (32.5%)	95 (26.4%)	1,330 (9.9%)	
20-29	1,776 (11.4%)	219 (12.0%)	57 (15.8%)	1,500 (11.2%)	
30-39	3,054 (19.6%)	323 (17.7%)	97 (26.9%)	2,634 (19.7%)	
40-49	2,859 (18.4%)	242 (13.3%)	53 (14.7%)	2,564 (19.2%)	
50-59	2,572 (16.5%)	189 (10.4%)	35 (9.7%)	2,348 (17.5%)	
60-69	1,879 (12.1%)	135 (7.4%)	13 (3.6%)	1,731 (12.9%)	
70-79	1,023 (6.6%)	88 (4.8%)	8 (2.2%)	927 (6.9%)	
80-89	384 (2.5%)	35 (1.9%)	2 (0.6%)	347 (2.6%)	
Sex					0.0003
Female	8,665 (55.7%)	929 (50.9%)	204 (56.7%)	7,532 (56.3%)	
Male	6,901 (44.3%)	896 (49.1%)	156 (43.3%)	5,849 (43.7%)	
Race/ethnicity					< 0.0001
LatinX/Hispanic ethnicity	4,303 (27.6%)	591 (32.4%)	158 (43.9%)	3,554 (26.6%)	
Black/African descent	1,368 (8.8%)	267 (14.6%)	45 (12.5%)	1,056 (7.9%)	
Asian descent	4,090 (26.3%)	211 (11.6%)	38 (10.6%)	3,841 (28.7%)	
White/European or middle eastern	4,788 (30.8%)	603 (33.0%)	100 (27.8%)	4,085 (30.5%)	
descent					
Other/unknown	1,017 (6.5%)	153 (8.4%)	19 (5.3%)	845 (6.3%)	
Charlson comorbidity index score				. , ,	0.44
Score 0	10,082 (64.8%)	1,218 (66.7%)	271 (75.3%)	8,593 (64.2%)	
Score 1	2,278 (14.6%)	225 (12.3%)	48 (13.3%)	2,005 (15.0%)	
Score 2	881 (5.7%)	60 (3.3%)	4 (1.1%)	817 (6.1%)	
Score 3+	1,141 (7.3%)	118 (6.5%)	11 (3.1%)	1,012 (7.6%)	
Missing (no visits in prior year)	1,184 (7.6%)	204 (11.2%)	26 (7.2%)	954 (7.1%)	
COVID-19 vaccination					
None	2.185 (14.0%)	1.825 (100.0%)	360 (100.0%)		
Complete primary series	, (,	,,	(
Johnson & Johnson	803 (5.2%)			803 (6.0%)	
Moderna	4.359 (28.0%)			4.359 (32.6%)	
Pfizer	8.219 (52.8%)			8.219 (61.4%)	
Month of SARS-CoV-2 infection	-, - (,				0.007
January 2022	3,120 (20.0%)	663 (36.3%)	65 (18.1%)	2,392 (17.9%)	
February 2022	1.280 (8.2%)	250 (13.7%)	26 (7.2%)	1.004 (7.5%)	
March 2022	791 (5.1%)	92 (5.0%)	13 (3.6%)	686 (5.1%)	
April 2022	1.090 (7.0%)	88 (4.8%)	10 (2.8%)	992 (7.4%)	
May 2022	1.210 (7.8%)	95 (5.2%)	21 (5.8%)	1.094 (8.2%)	
lune 2022	1.837 (11.8%)	152 (8.3%)	53 (14.7%)	1.632 (12.2%)	
luly 2022	2,770 (17.8%)	212 (11.6%)	75 (20.8%)	2,483 (18.6%)	
August 2022	2,263 (14.5%)	182 (10.0%)	62 (17.2%)	2.019 (15.1%)	1
Sentember 2022	1.070 (6.9%)	83 (4.5%)	32 (8.9%)	955 (7.1%)	
October 2022	135 (0.9%)	8 (0.4%)	3 (0.8%)	124 (0.9%)	
Months from last vaccine dose to SARS-			5 (0.0,0)	(0.070)	1
CoV-2 infection					
Mean (standard deviation)	6.5 (3.7)			6.5 (3.7)	
	- 1 7	1	1		1

Characteristic	All n (%)	Not vaccinated, no prior reported infection n (%)	Not vaccinated, prior reported infection n (%)	Vaccinated n (%)	p-value ¹
Median (25 th percentile, 75 th percentile)	6.3 (3.7, 8.6)			6.3 (3.7, 8.6)	
Immune compromising conditions ²					
Any immune compromising condition	1,092 (7.0%)	92 (5.0%)	16 (4.4%)	984 (7.4%)	0.0009
Severe clinical outcomes					
Any hospitalization	483 (3.1%)	164 (9.0%)	5 (1.4%)	314 (2.3%)	<0.0001

¹Wilcoxon rank sum test; Pearson's Chi-squared test

²Immune compromising conditions: HIV, organ transplant, cancer, rheumatologic/inflammatory conditions, and other immune deficiencies.

Table 2: Association between mutation groups ¹ and vaccine status (pooling over complete and boosted) among
persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 1,
2022 - October 31, 2022 (N=15,566) ²

SNP/group	Not vaccinated, no recorded prior infection	Not vaccinated, recorded prior infection			Vaccinated, regardless of prior infection status			
		aRR (95% CI)	p (raw)	p (FDR)	aRR (95% CI)	p (raw)	p (FDR)	
group64	Reference	1.26 (0.82- 1.93)	0.2845	0.97743	1.22 (0.96- 1.56)	0.1097	0.72385	
ORF10:L37F	Reference	1.00 (0.61- 1.62)	0.9849	0.98491	1.18 (0.91- 1.53)	0.2210	0.86611	
ORF1b:N498I	Reference	0.96 (0.57- 1.63)	0.8889	0.97743	1.13 (0.92- 1.40)	0.2404	0.86611	
group45	Reference	1.13 (0.96- 1.34)	0.1504	0.97743	1.10 (1.01- 1.19)	0.0282	0.46532	
ORF1a:V2857A	Reference	1.38 (0.84- 2.29)	0.2047	0.97743	1.09 (0.86- 1.39)	0.4703	0.90946	
S:D1259H	Reference	1.06 (0.87- 1.29)	0.5509	0.97743	1.08 (0.99- 1.19)	0.0834	0.68786	
S:T76I	Reference	1.25 (0.80- 1.95)	0.3219	0.97743	1.07 (0.83- 1.40)	0.5906	0.91512	
N:S33C	Reference	1.07 (0.78- 1.45)	0.6751	0.97743	1.06 (0.92- 1.24)	0.4194	0.89674	
group25	Reference	1.04 (0.88- 1.23)	0.6343	0.97743	1.04 (0.95- 1.14)	0.4105	0.89674	
S:V70L	Reference	0.89 (0.62- 1.29)	0.5376	0.97743	1.04 (0.90- 1.20)	0.6297	0.91512	
group7	Reference	0.95 (0.66- 1.36)	0.7830	0.97743	1.04 (0.87- 1.24)	0.6892	0.91512	
ORF1a:F3604L	Reference	0.98 (0.59- 1.64)	0.9420	0.97743	1.04 (0.84- 1.28)	0.7322	0.91512	
group19	Reference	1.02 (0.91- 1.15)	0.6952	0.97743	1.03 (0.98- 1.09)	0.2357	0.86611	
N:S33G	Reference	0.97 (0.85- 1.10)	0.6454	0.97743	1.03 (0.98- 1.09)	0.2335	0.86611	
ORF1a:G3676S	Reference	1.02 (0.90- 1.16)	0.7179	0.97743	1.03 (0.97- 1.09)	0.4073	0.89674	
ORF1b:F685Y	Reference	1.01 (0.84- 1.21)	0.9202	0.97743	1.03 (0.95- 1.12)	0.4348	0.89674	
S:H69L	Reference	0.61 (0.36- 1.03)	0.0638	0.97743	1.03 (0.88- 1.19)	0.7379	0.91512	
group11	Reference	0.99 (0.88- 1.11)	0.8721	0.97743	1.02 (0.97- 1.08)	0.4105	0.89674	
S:Q493R	Reference	0.92 (0.78- 1.10)	0.3603	0.97743	1.02 (0.95- 1.09)	0.6063	0.91512	
group12	Reference	0.92 (0.74- 1.15)	0.4770	0.97743	1.02 (0.92- 1.13)	0.6863	0.91512	
S:V70I	Reference	1.03 (0.89- 1.19)	0.6590	0.97743	1.01 (0.95- 1.08)	0.6802	0.91512	
S:A21764-TACATG	Reference	1.04 (0.92- 1.18)	0.5241	0.97743	1.01 (0.95- 1.07)	0.8278	0.93114	
group6	Reference	0.99 (0.86- 1.13)	0.8384	0.97743	1.01 (0.94- 1.08)	0.7811	0.92055	
S:R408S	Reference	1.01 (0.87- 1.18)	0.8820	0.97743	1.01 (0.93- 1.09)	0.8725	0.93114	
ORF1a:S3675T	Reference	0.96 (0.80- 1.16)	0.7049	0.97743	1.01 (0.92- 1.10)	0.9048	0.93114	
group20	Reference	1.00 (0.88- 1.15)	0.9478	0.97743	1.00 (0.94- 1.07)	0.9311	0.93114	
group26	Reference	1.06 (0.88- 1.29)	0.5288	0.97743	0.99 (0.92- 1.06)	0.7487	0.91512	
ORF1a:P1693R	Reference	1.06 (0.68- 1.63)	0.8043	0.97743	0.99 (0.81- 1.21)	0.9139	0.93114	
group4	Reference	1.06 (0.88- 1.28)	0.5443	0.97743	0.98 (0.91- 1.05)	0.4961	0.90946	
N:D343G	Reference	0.59 (0.31- 1.11)	0.1019	0.97743	0.90 (0.75- 1.08)	0.2628	0.86611	
N:S33F	Reference	1.34 (0.94- 1.92)	0.1096	0.97743	0.89 (0.71- 1.11)	0.2887	0.86611	
ORF1a:S2083I	Reference	1.06 (0.74- 1.53)	0.7369	0.97743	0.87 (0.76- 1.00)	0.0431	0.47401	
ORF1a:L2084I	Reference	0.90 (0.58- 1.39)	0.6213	0.97743	0.84 (0.72- 0.97)	0.0177	0.46532	

¹ Mutations with Pearson pairwise correlation >0.70 combined into groups for analysis:

- group 4: M:D3G, ORF1a:I3758V, ORF1a:K856R, S:A67V, S:G496S, S:N211I, S:N856K, S:R346K,
- S:S371P, S:T22204+GAGCCAGAA, S:T547K, S:T951
- group 6: N:S413R, ORF1a:F3677L, ORF1a:G1307S, ORF1a:L3027F, ORF1a:S135R, ORF1a:T3090I, ORF1a:T842I, ORF1b:R1315C, ORF1b:T2163I, ORF3a:T223I, S:D405N, S:G142D, S:L24S, S:T19I, S:T376A, S:V213G group 7: S:L452Q, S:S704L
- group 11: S:E484A, S:N501Y, S:Q498R, S:S477N, S:T478K, S:Y505H
- group 12: ORF1a:L3201F, ORF6:D61L
- group 19: S:S371F, S:S373P, S:S375F
- group 20: S:K417N, S:N440K
- group 25: M:D3N, S:F486V, S:L452R
- group 26: ORF1a:A2710T, ORF1a:L3674F, S:G21986-GTGTTTATT, S:G22193-ATT, S:G446S, S:L981F
- group 45: S:A27S, S:C1254*
- group 64: N:P151S, ORF1a:F143L

² Adjusted risk ratios derived from Poisson regression models to assess the association of immunity status with each mutation group adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection.

Supplemental Figure 1. Cohort flowchart





Supplemental Figure 2: Pearson correlations of SNP presence in specimens, before and after clustering.

Supplemental Figure 3. Phylogenies of 15,045 Omicron genomes colored by group. Mutations in group 52 (top) represent a clade defined by the BA.2.12.1 subvariant (in blue). Mutations in group 4 (bottom) fall into a subclade of BA.4 (in yellow).



Supplemental Figure 4. Persons with SARS-CoV-2 infection tested by Kaiser Permanente Northern California stratified by subvariant by week from January 1, 2022 to October 31, 2022





Supplemental Figure 5. Proportion of specimens with a given SNP or group, by month of 2022

Supplemental Figure 6. Phylogeny of 15,045 Omicron genomes sampled between 1/1/2022 and 9/25/22. Branch lengths represent divergence from Wuhan reference genome and nodes are colored by vaccination status. Vaccinated category includes primary series and primary plus booster.



Supplemental Table 1: Association between SNP presence and vaccine status (pooling over complete and boosted) among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 1, 2022 - October 31, 2022 (N=15,566).

	Not vaccinated, n infec	o recorded prior tion	Not vaccinated, recorded prior infection		Vaccinated, regardless of prior infection status	
SNP	N (%)	Adjusted RR (95% Cl)	N (%)	N (%) Adjusted RR (95% CI)		Adjusted RR (95% CI)
ORF1A:F143L	53 (2.9%)	Reference	24 (6.7%)	1.38 (0.85- 2.25)	705 (5.3%)	1.29 (0.97- 1.72)
N:P151S	65 (3.6%)	Reference	26 (7.2%)	1.19 (0.75- 1.87)	773 (5.8%)	1.18 (0.91- 1.54)
ORF10:L37F	63 (3.5%)	Reference	22 (6.1%)	1.00 (0.61- 1.62)	820 (6.1%)	1.18 (0.91- 1.53)
ORF1B:N498I	113 (6.2%)	Reference	16 (4.4%)	0.96 (0.57- 1.63)	729 (5.4%)	1.13 (0.92- 1.40)
S:N211I	499 (27.3%)	Reference	57 (15.8%)	1.11 (0.84- 1.46)	2,132 (15.9%)	1.12 (1.01- 1.24)
S:C1254*	615 (33.7%)	Reference	164 (45.6%)	1.15 (0.97- 1.37)	5,506 (41.1%)	1.11 (1.02- 1.21)
ORF1A:V2857A	82 (4.5%)	Reference	19 (5.3%)	1.38 (0.84- 2.29)	744 (5.6%)	1.09 (0.86- 1.39)
S:D1259H	561 (30.7%)	Reference	121 (33.6%)	1.06 (0.87- 1.29)	4,756 (35.5%)	1.08 (0.99- 1.19)
S:T76I	64 (3.5%)	Reference	28 (7.8%)	1.25 (0.80- 1.95)	755 (5.6%)	1.07 (0.83- 1.40)
N:S33C	209 (11.5%)	Reference	51 (14.2%)	1.07 (0.78- 1.45)	1,770 (13.2%)	1.06 (0.92- 1.24)
S:T22204+GAGCCAGAA	742 (40.7%)	Reference	84 (23.3%)	1.07 (0.85- 1.34)	3,088 (23.1%)	1.05 (0.97- 1.15)
S:G22193-ATT	780 (42.7%)	Reference	88 (24.4%)	1.07 (0.86- 1.34)	3,237 (24.2%)	1.05 (0.97- 1.14)
S:S371P	785 (43.0%)	Reference	91 (25.3%)	1.10 (0.88- 1.36)	3,254 (24.3%)	1.05 (0.96- 1.13)
S:F486V	505 (27.7%)	Reference	186 (51.7%)	1.04 (0.88- 1.23)	5,949 (44.5%)	1.04 (0.95- 1.14)
S:V70L	235 (12.9%)	Reference	33 (9.2%)	0.89 (0.62- 1.29)	1,325 (9.9%)	1.04 (0.90- 1.20)
ORF1A:F3604L	112 (6.1%)	Reference	17 (4.7%)	0.98 (0.59- 1.64)	709 (5.3%)	1.04 (0.84- 1.28)
N:S33G	1,513 (82.9%)	Reference	286 (79.4%)	0.97 (0.85- 1.10)	11,437 (85.5%)	1.03 (0.98- 1.09)
S:S371F	1,626 (89.1%)	Reference	341 (94.7%)	1.02 (0.91- 1.15)	12,659 (94.6%)	1.03 (0.98- 1.09)
S:S373P	1,628 (89.2%)	Reference	342 (95.0%)	1.02 (0.91- 1.15)	12,717 (95.0%)	1.03 (0.98- 1.09)
S:S375F	1,629 (89.3%)	Reference	343 (95.3%)	1.03 (0.91- 1.15)	12,727 (95.1%)	1.03 (0.98- 1.09)
S:K417N	1,180 (64.7%)	Reference	254 (70.6%)	1.03 (0.90- 1.18)	9,298 (69.5%)	1.03 (0.97- 1.10)
ORF1A:G3676S	1,376 (75.4%)	Reference	285 (79.2%)	1.02 (0.90- 1.16)	10,715 (80.1%)	1.03 (0.97- 1.09)
S:E484A	1,640 (89.9%)	Reference	333 (92.5%)	0.99 (0.88- 1.12)	12,662 (94.6%)	1.03 (0.97- 1.08)
S:Y505H	1,643 (90.0%)	Reference	334 (92.8%)	0.99 (0.88- 1.12)	12,699 (94.9%)	1.03 (0.97- 1.08)
ORF1A:L3027F	844 (46.2%)	Reference	253 (70.3%)	1.00 (0.87- 1.16)	9,562 (71.5%)	1.03 (0.96- 1.11)
ORF1B:F685Y	693 (38.0%)	Reference	137 (38.1%)	1.01 (0.84- 1.21)	5,570 (41.6%)	1.03 (0.95- 1.12)
ORF1A:F3677L	767 (42.0%)	Reference	223 (61.9%)	0.98 (0.84- 1.14)	8,689 (64.9%)	1.03 (0.95- 1.11)
S:G496S	802 (43.9%)	Reference	82 (22.8%)	0.99 (0.79- 1.25)	3,188 (23.8%)	1.03 (0.95- 1.11)
S:H69L	238 (13.0%)	Reference	15 (4.2%)	0.61 (0.36- 1.03)	952 (7.1%)	1.03 (0.88- 1.19)
S:S704L	141 (7.7%)	Reference	38 (10.6%)	0.96 (0.67- 1.38)	1,630 (12.2%)	1.03 (0.87- 1.24)
S:N501Y	1,652 (90.5%)	Reference	334 (92.8%)	0.99 (0.88- 1.11)	12,716 (95.0%)	1.02 (0.97- 1.08)

	Not vaccinated, infe	no recorded prior ction	Not vaccinated, recorded prior infection		Vaccinated, regardless of prior infection status	
SNP	N (%)	Adjusted RR (95% Cl)	N (%)	N (%) Adjusted RR (95% CI)		Adjusted RR (95% CI)
S:Q498R	1,652 (90.5%)	Reference	332 (92.2%)	0.98 (0.87- 1.11)	12,695 (94.9%)	1.02 (0.97- 1.08)
S:S477N	1,612 (88.3%)	Reference	326 (90.6%)	0.98 (0.87- 1.10)	12,528 (93.6%)	1.02 (0.97- 1.08)
S:T478K	1,643 (90.0%)	Reference	331 (91.9%)	0.98 (0.87- 1.11)	12,651 (94.5%)	1.02 (0.97- 1.08)
ORF1A:S135R	862 (47.2%)	Reference	254 (70.6%)	0.98 (0.86- 1.13)	9,651 (72.1%)	1.02 (0.95- 1.10)
ORF1A:T842I	862 (47.2%)	Reference	255 (70.8%)	0.99 (0.86- 1.14)	9,632 (72.0%)	1.02 (0.95- 1.10)
ORF1B:R1315C	868 (47.6%)	Reference	259 (71.9%)	1.00 (0.87- 1.15)	9,701 (72.5%)	1.02 (0.95- 1.10)
S:T376A	860 (47.1%)	Reference	257 (71.4%)	1.00 (0.87- 1.15)	9,602 (71.8%)	1.02 (0.95- 1.10)
S:V213G	863 (47.3%)	Reference	257 (71.4%)	0.99 (0.86- 1.14)	9,670 (72.3%)	1.02 (0.95- 1.10)
N:S413R	866 (47.5%)	Reference	257 (71.4%)	0.99 (0.86- 1.14)	9,672 (72.3%)	1.02 (0.95- 1.09)
ORF1A:T3090I	866 (47.5%)	Reference	258 (71.7%)	1.00 (0.87- 1.14)	9,686 (72.4%)	1.02 (0.95- 1.09)
ORF1B:T2163I	865 (47.4%)	Reference	258 (71.7%)	1.00 (0.87- 1.14)	9,654 (72.1%)	1.02 (0.95- 1.09)
ORF3A:T223I	865 (47.4%)	Reference	257 (71.4%)	1.00 (0.87- 1.15)	9,668 (72.3%)	1.02 (0.95- 1.09)
S:D405N	858 (47.0%)	Reference	256 (71.1%)	1.00 (0.87- 1.15)	9,556 (71.4%)	1.02 (0.95- 1.09)
S:Q493R	1,141 (62.5%)	Reference	145 (40.3%)	0.92 (0.78- 1.10)	6,743 (50.4%)	1.02 (0.95- 1.09)
S:T19I	864 (47.3%)	Reference	257 (71.4%)	0.99 (0.86- 1.14)	9,667 (72.2%)	1.02 (0.95- 1.09)
ORF6:D61L	424 (23.2%)	Reference	91 (25.3%)	0.91 (0.72- 1.14)	4,440 (33.2%)	1.02 (0.92- 1.13)
S:V70I	1,078 (59.1%)	Reference	229 (63.6%)	1.03 (0.89- 1.19)	7,707 (57.6%)	1.01 (0.95- 1.08)
S:A21764-TACATG	1,477 (80.9%)	Reference	295 (81.9%)	1.04 (0.92- 1.18)	9,809 (73.3%)	1.01 (0.95- 1.07)
ORF1A:G1307S	866 (47.5%)	Reference	258 (71.7%)	1.00 (0.87- 1.14)	9,633 (72.0%)	1.01 (0.94- 1.09)
S:G142D	889 (48.7%)	Reference	257 (71.4%)	0.98 (0.85- 1.13)	9,732 (72.7%)	1.01 (0.94- 1.08)
S:L24S	710 (38.9%)	Reference	213 (59.2%)	1.01 (0.87- 1.18)	7,962 (59.5%)	1.01 (0.93- 1.09)
S:R408S	705 (38.6%)	Reference	217 (60.3%)	1.01 (0.87- 1.18)	7,727 (57.7%)	1.01 (0.93- 1.09)
M:D3N	453 (24.8%)	Reference	163 (45.3%)	1.01 (0.85- 1.21)	5,285 (39.5%)	1.01 (0.92- 1.12)
S:L452R	433 (23.7%)	Reference	153 (42.5%)	1.02 (0.85- 1.23)	4,878 (36.5%)	1.01 (0.92- 1.12)
ORF1A:S3675T	527 (28.9%)	Reference	143 (39.7%)	0.96 (0.80- 1.16)	5,891 (44.0%)	1.01 (0.92- 1.10)
S:A27S	207 (11.3%)	Reference	73 (20.3%)	1.07 (0.82- 1.39)	2,309 (17.3%)	1.01 (0.87- 1.17)
S:L452Q	99 (5.4%)	Reference	28 (7.8%)	0.96 (0.63- 1.47)	1,116 (8.3%)	1.01 (0.82- 1.25)
ORF1A:L3201F	365 (20.0%)	Reference	72 (20.0%)	0.88 (0.69- 1.14)	3,801 (28.4%)	1.00 (0.89- 1.11)
S:N440K	1,221 (66.9%)	Reference	251 (69.7%)	0.97 (0.85- 1.11)	9,418 (70.4%)	0.99 (0.93- 1.05)
ORF1A:K856R	954 (52.3%)	Reference	103 (28.6%)	1.05 (0.86- 1.29)	3,747 (28.0%)	0.99 (0.92- 1.07)
S:A67V	974 (53.4%)	Reference	109 (30.3%)	1.08 (0.88- 1.31)	3,848 (28.8%)	0.99 (0.92- 1.06)
S:L981F	972 (53.3%)	Reference	107 (29.7%)	1.06 (0.87- 1.29)	3,830 (28.6%)	0.99 (0.92- 1.06)
S:T547K	966 (52.9%)	Reference	105 (29.2%)	1.06 (0.86- 1.29)	3,784 (28.3%)	0.99 (0.92- 1.06)
S:G446S	567 (31.1%)	Reference	53 (14.7%)	0.91 (0.68- 1.20)	2,220 (16.6%)	0.99 (0.90- 1.09)

	Not vaccinated, no recorded prior infection		Not vaccina	ated, recorded prior infection	Vaccinated, regardless of prior infection status		
SNP	N (%)	Adjusted RR (95% Cl)	N (%)	Adjusted RR (95% CI)	N (%)	Adjusted RR (95% CI)	
ORF1A:P1693R	119 (6.5%)	Reference	25 (6.9%)	1.06 (0.68- 1.63)	790 (5.9%)	0.99 (0.81- 1.21)	
ORF1A:A2710T	978 (53.6%)	Reference	110 (30.6%)	1.08 (0.88- 1.31)	3,878 (29.0%)	0.98 (0.91- 1.06)	
ORF1A:I3758V	974 (53.4%)	Reference	109 (30.3%)	1.08 (0.88- 1.31)	3,834 (28.7%)	0.98 (0.91- 1.06)	
S:G21986-GTGTTTATT	967 (53.0%)	Reference	106 (29.4%)	1.06 (0.87- 1.30)	3,767 (28.2%)	0.98 (0.91- 1.06)	
S:T95I	974 (53.4%)	Reference	108 (30.0%)	1.07 (0.88- 1.30)	3,839 (28.7%)	0.98 (0.91- 1.06)	
M:D3G	965 (52.9%)	Reference	106 (29.4%)	1.05 (0.86- 1.29)	3,779 (28.2%)	0.98 (0.91- 1.05)	
S:R346K	660 (36.2%)	Reference	89 (24.7%)	1.28 (1.03- 1.60)	2,600 (19.4%)	0.98 (0.90- 1.07)	
S:N856K	986 (54.0%)	Reference	109 (30.3%)	1.06 (0.87- 1.29)	3,860 (28.8%)	0.97 (0.90- 1.05)	
ORF1A:L3674F	521 (28.5%)	Reference	56 (15.6%)	1.05 (0.80- 1.38)	2,013 (15.0%)	0.95 (0.86- 1.05)	
N:D343G	160 (8.8%)	Reference	10 (2.8%)	0.59 (0.31- 1.11)	624 (4.7%)	0.90 (0.75- 1.08)	
N:S33F	93 (5.1%)	Reference	44 (12.2%)	1.34 (0.94- 1.92)	974 (7.3%)	0.89 (0.71- 1.11)	
ORF1A:S2083I	308 (16.9%)	Reference	33 (9.2%)	1.06 (0.74- 1.53)	1,082 (8.1%)	0.87 (0.76- 1.00)	
ORF1A:L2084I	255 (14.0%)	Reference	22 (6.1%)	0.90 (0.58- 1.39)	865 (6.5%)	0.84 (0.72- 0.97)	

¹ Poisson regression models to assess the association of breakthrough infection with each individual mutation adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection. None of the p-values were significant after adjustment for multiple testing.

Supplemental Table 2: Association between SNP presence and vaccine status (separating out complete and boosted) among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 1, 2022 – October 31, 2022 (N=15,566)

SNP	Not vaccinated, no prior recorded infection	Not vaccinated, prior recorded infection (95% CI)	Primary vaccine series complete (95% CI)	Boosted (95% CI)	
ORF1a:F143L	Reference	1.38 (0.85- 2.24)	1.43 (1.05- 1.95)	1.22 (0.91- 1.63)	
ORF10:L37F	Reference	1.00 (0.61- 1.62)	1.17 (0.88- 1.56)	1.18 (0.90- 1.55)	
S:N211I	Reference	1.11 (0.84- 1.46)	1.10 (0.98- 1.22)	1.16 (1.04- 1.31)	
ORF1b:N498I	Reference	0.96 (0.57- 1.63)	1.12 (0.90- 1.40)	1.15 (0.91- 1.44)	
N:P151S	Reference	1.18 (0.75- 1.87)	1.24 (0.94- 1.65)	1.15 (0.88- 1.50)	
ORF1a:F3604L	Reference	0.99 (0.59- 1.65)	0.97 (0.77- 1.22)	1.12 (0.89- 1.41)	
S:C1254*	Reference	1.15 (0.97- 1.37)	1.10 (1.01- 1.21)	1.11 (1.01- 1.22)	
S:D1259H	Reference	1.06 (0.87- 1.30)	1.06 (0.96- 1.17)	1.11 (1.00- 1.22)	
S:T76I	Reference	1.25 (0.80- 1.96)	1.05 (0.79- 1.41)	1.09 (0.83- 1.42)	
N:S33C	Reference	1.07 (0.79- 1.45)	1.06 (0.90- 1.25)	1.07 (0.91- 1.25)	
S:S371P	Reference	1.10 (0.88- 1.36)	1.04 (0.95- 1.13)	1.06 (0.96- 1.16)	
ORF1b:F685Y	Reference	1.01 (0.84- 1.22)	1.02 (0.93- 1.11)	1.05 (0.96- 1.15)	
S:T22204+GAGCCAGAA	Reference	1.07 (0.85- 1.34)	1.06 (0.97- 1.16)	1.05 (0.95- 1.15)	
N:S33G	Reference	0.97 (0.86- 1.10)	1.03 (0.97- 1.09)	1.04 (0.98- 1.11)	
S:S371F	Reference	1.02 (0.91- 1.15)	1.03 (0.97- 1.09)	1.04 (0.98- 1.10)	
S:S373P	Reference	1.02 (0.91- 1.15)	1.03 (0.97- 1.09)	1.04 (0.98- 1.10)	
S:S375F	Reference	1.03 (0.91- 1.15)	1.03 (0.97- 1.09)	1.04 (0.98- 1.10)	
ORF1a:L3027F	Reference	1.00 (0.87- 1.16)	1.02 (0.95- 1.11)	1.04 (0.96- 1.12)	
S:F486V	Reference	1.04 (0.88- 1.23)	1.03 (0.93- 1.14)	1.04 (0.95- 1.15)	
S:G22193-ATT	Reference	1.07 (0.86- 1.34)	1.06 (0.97- 1.16)	1.04 (0.95- 1.15)	
S:E484A	Reference	0.99 (0.88- 1.12)	1.02 (0.97- 1.08)	1.03 (0.97- 1.09)	
S:N501Y	Reference	0.99 (0.88- 1.11)	1.02 (0.97- 1.08)	1.03 (0.97- 1.09)	
S:S477N	Reference	0.98 (0.87- 1.10)	1.02 (0.97- 1.09)	1.03 (0.97- 1.09)	
S:T478K	Reference	0.98 (0.87- 1.11)	1.02 (0.96- 1.08)	1.03 (0.97- 1.09)	
S:Y505H	Reference	0.99 (0.88- 1.12)	1.03 (0.97- 1.09)	1.03 (0.97- 1.09)	
S:K417N	Reference	1.03 (0.90- 1.18)	1.03 (0.96- 1.10)	1.03 (0.96- 1.10)	
ORF1a:G3676S	Reference	1.02 (0.90- 1.16)	1.02 (0.96- 1.09)	1.03 (0.96- 1.09)	
ORF1a:F3677L	Reference	0.98 (0.84- 1.14)	1.03 (0.95- 1.12)	1.03 (0.95- 1.11)	
ORF1a:V2857A	Reference	1.37 (0.83- 2.27)	1.16 (0.90- 1.50)	1.03 (0.80- 1.33)	
S:Q498R	Reference	0.98 (0.87- 1.11)	1.02 (0.96- 1.08)	1.02 (0.97- 1.08)	
N:S413R	Reference	0.99 (0.86- 1.14)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF1a:G1307S	Reference	1.00 (0.87- 1.14)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF1a:S135R	Reference	0.98 (0.86- 1.13)	1.01 (0.94- 1.10)	1.02 (0.95- 1.10)	

SNP	Not vaccinated, no prior recorded infection	Not vaccinated, prior recorded infection (95% CI)	Primary vaccine series complete (95% Cl)	Boosted (95% CI)	
ORF1a:T3090I	Reference	1.00 (0.87- 1.14)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF1a:T842I	Reference	0.99 (0.86- 1.14)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF1b:R1315C	Reference	1.00 (0.87- 1.15)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF1b:T2163I	Reference	1.00 (0.87- 1.15)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
ORF3a:T223I	Reference	1.00 (0.87- 1.15)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
S:D405N	Reference	1.00 (0.87- 1.15)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
S:T19I	Reference	0.99 (0.86- 1.14)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
S:T376A	Reference	1.00 (0.87- 1.15)	1.01 (0.93- 1.09)	1.02 (0.95- 1.10)	
S:V213G	Reference	0.99 (0.86- 1.14)	1.01 (0.94- 1.10)	1.02 (0.95- 1.10)	
S:Q493R	Reference	0.92 (0.78- 1.10)	1.02 (0.95- 1.09)	1.02 (0.95- 1.09)	
M:D3N	Reference	1.01 (0.85- 1.21)	0.99 (0.89- 1.11)	1.02 (0.93- 1.13)	
S:G496S	Reference	0.99 (0.79- 1.25)	1.03 (0.95- 1.12)	1.02 (0.93- 1.12)	
orf6:d61l	Reference	0.91 (0.72- 1.14)	1.01 (0.90- 1.13)	1.02 (0.92- 1.14)	
S:G142D	Reference	0.98 (0.85- 1.13)	1.00 (0.92- 1.08)	1.01 (0.94- 1.09)	
S:V70I	Reference	1.03 (0.89- 1.19)	1.02 (0.95- 1.10)	1.01 (0.94- 1.08)	
S:L24S	Reference	1.01 (0.87- 1.18)	1.01 (0.93- 1.10)	1.01 (0.93- 1.10)	
S:R408S	Reference	1.01 (0.87- 1.18)	1.00 (0.91- 1.09)	1.01 (0.93- 1.10)	
ORF1a:S3675T	Reference	0.97 (0.80- 1.16)	1.00 (0.90- 1.11)	1.01 (0.92- 1.11)	
S:L452R	Reference	1.02 (0.85- 1.23)	1.01 (0.91- 1.13)	1.01 (0.91- 1.13)	
S:V70L	Reference	0.89 (0.62- 1.28)	1.06 (0.91- 1.23)	1.01 (0.86- 1.19)	
S:H69L	Reference	0.61 (0.36- 1.03)	1.03 (0.88- 1.21)	1.01 (0.85- 1.20)	
S:S704L	Reference	0.96 (0.67- 1.37)	1.09 (0.90- 1.32)	1.01 (0.84- 1.21)	
S:A21764-TACATG	Reference	1.04 (0.92- 1.18)	1.01 (0.95- 1.07)	1.00 (0.94- 1.07)	
ORF1a:L3201F	Reference	0.88 (0.69- 1.14)	0.99 (0.88- 1.12)	1.00 (0.89- 1.12)	
S:A27S	Reference	1.07 (0.82- 1.39)	1.03 (0.88- 1.21)	1.00 (0.86- 1.16)	
S:N440K	Reference	0.97 (0.84- 1.11)	0.99 (0.93- 1.06)	0.99 (0.92- 1.05)	
S:L452Q	Reference	0.96 (0.63- 1.46)	1.05 (0.84- 1.33)	0.99 (0.79- 1.23)	
ORF1a:K856R	Reference	1.05 (0.86- 1.29)	1.00 (0.92- 1.08)	0.98 (0.90- 1.06)	
S:L981F	Reference	1.06 (0.87- 1.29)	0.99 (0.92- 1.07)	0.98 (0.90- 1.06)	
S:G446S	Reference	0.91 (0.68- 1.20)	1.00 (0.90- 1.11)	0.98 (0.88- 1.10)	
S:A67V	Reference	1.08 (0.88- 1.31)	1.00 (0.92- 1.08)	0.97 (0.89- 1.06)	
S:T547K	Reference	1.06 (0.86- 1.29)	0.99 (0.92- 1.07)	0.97 (0.89- 1.06)	
ORF1a:A2710T	Reference	1.08 (0.88- 1.31)	0.99 (0.91- 1.07)	0.97 (0.89- 1.05)	
ORF1a:I3758V	Reference	1.08 (0.88- 1.31)	0.99 (0.92- 1.07)	0.97 (0.89- 1.05)	
S:G21986-GTGTTTATT	Reference	1.06 (0.87- 1.30)	0.99 (0.92- 1.07)	0.97 (0.89- 1.05)	

SNP	Not vaccinated, no prior recorded infection	Not vaccinated, prior recorded infection (95% CI)	Primary vaccine series complete (95% CI)	Boosted (95% CI)
S:T95I	Reference	1.07 (0.88- 1.31)	0.99 (0.92- 1.07)	0.97 (0.89- 1.05)
S:R346K	Reference	1.28 (1.03- 1.60)	0.99 (0.90- 1.09)	0.97 (0.88- 1.08)
ORF1a:P1693R	Reference	1.05 (0.68- 1.63)	1.01 (0.81- 1.26)	0.97 (0.78- 1.21)
M:D3G	Reference	1.05 (0.86- 1.29)	0.99 (0.91- 1.07)	0.96 (0.88- 1.05)
S:N856K	Reference	1.06 (0.87- 1.29)	0.98 (0.91- 1.06)	0.96 (0.88- 1.04)
N:D343G	Reference	0.59 (0.31- 1.11)	0.87 (0.72- 1.06)	0.95 (0.77- 1.16)
ORF1a:L3674F	Reference	1.05 (0.80- 1.39)	0.96 (0.87- 1.07)	0.94 (0.83- 1.05)
n:s33f	Reference	1.34 (0.94- 1.92)	0.94 (0.73- 1.20)	0.86 (0.69- 1.08)
ORF1a:S2083I	Reference	1.07 (0.74- 1.53)	0.92 (0.80- 1.06)	0.80 (0.68- 0.93)
ORF1a:L2084I	Reference	0.90 (0.58- 1.40)	0.94 (0.81- 1.10)	0.69 (0.58- 0.82)

¹ Poisson regression models to assess the association of breakthrough infection with each individual mutation adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection. None of the p-values were significant after adjustment for multiple testing.

Supplemental Table 3: Association between mutation groups¹ and vaccine status (separating complete and boosted) among persons included in this analysis with SARS-CoV-2 infection with Omicron variant in Northern California, January 2022-October 2022 (N=15,566)²

	Not									
	No prior infection	Not vaccinated, Recorded prior infection			Vaccinated with complete series, regardless of prior infection status			Vaccinated with more than complete series, regardless of prior infection status		
SNP or group		aRR (95% CI)	p (raw)	p (FDR)	aRR (95% CI)	p (raw)	p (FDR)	aRR (95% CI)	p (raw)	p (FDR)
ORF10:L37F	Reference	1.00 (0.61- 1.62)	0.9854	0.99996	1.17 (0.88- 1.56)	0.2897	0.98013	1.18 (0.90- 1.55)	0.2188	0.75760
group64	Reference	1.26 (0.82- 1.93)	0.2893	0.99996	1.31 (1.00- 1.71)	0.0460	0.63809	1.17 (0.91- 1.51)	0.2127	0.75760
ORF1b:N498I	Reference	0.96 (0.57- 1.63)	0.8930	0.99996	1.12 (0.90- 1.40)	0.3044	0.98013	1.15 (0.91- 1.44)	0.2418	0.75760
ORF1a:F3604L	Reference	0.99 (0.59- 1.65)	0.9670	0.99996	0.97 (0.77- 1.22)	0.8029	0.99285	1.12 (0.89- 1.41)	0.3409	0.84737
S:D1259H	Reference	1.06 (0.87- 1.30)	0.5325	0.99996	1.06 (0.96- 1.17)	0.2355	0.98013	1.11 (1.00- 1.22)	0.0437	0.38280
group45	Reference	1.13 (0.96- 1.34)	0.1487	0.99996	1.09 (1.00- 1.20)	0.0532	0.63809	1.10 (1.01- 1.20)	0.0299	0.34911
S:T76I	Reference	1.25 (0.80- 1.96)	0.3213	0.99996	1.05 (0.79- 1.41)	0.7269	0.99285	1.09 (0.83- 1.42)	0.5496	0.93632
N:S33C	Reference	1.07 (0.79- 1.45)	0.6744	0.99996	1.06 (0.90- 1.25)	0.4647	0.98013	1.07 (0.91- 1.25)	0.4358	0.84737
ORF1b:F685Y	Reference	1.01 (0.84- 1.22)	0.9039	0.99996	1.02 (0.93- 1.11)	0.7211	0.99285	1.05 (0.96- 1.15)	0.2874	0.77368
N:S33G	Reference	0.97 (0.86- 1.10)	0.6580	0.99996	1.03 (0.97- 1.09)	0.4080	0.98013	1.04 (0.98- 1.11)	0.1683	0.75760
group19	Reference	1.02 (0.91- 1.15)	0.6887	0.99996	1.03 (0.97- 1.09)	0.3374	0.98013	1.04 (0.98- 1.10)	0.2138	0.75760
group25	Reference	1.04 (0.88- 1.23)	0.6335	0.99996	1.03 (0.93- 1.14)	0.5399	0.98077	1.04 (0.95- 1.15)	0.3822	0.84737
ORF1a:G3676S	Reference	1.02 (0.90- 1.16)	0.7164	0.99996	1.02 (0.96- 1.09)	0.4624	0.98013	1.03 (0.96- 1.09)	0.4181	0.84737
group12	Reference	0.92 (0.74- 1.15)	0.4800	0.99996	1.01 (0.91- 1.13)	0.8274	0.99285	1.03 (0.92- 1.14)	0.6258	0.93632
ORF1a:V2857A	Reference	1.37 (0.83- 2.27)	0.2144	0.99996	1.16 (0.90- 1.50)	0.2416	0.98013	1.03 (0.80- 1.33)	0.8122	0.93632
group11	Reference	0.99 (0.88- 1.11)	0.8758	0.99996	1.02 (0.96- 1.08)	0.4901	0.98013	1.02 (0.97- 1.09)	0.4009	0.84737
S:Q493R	Reference	0.92 (0.78- 1.10)	0.3606	0.99996	1.02 (0.95- 1.09)	0.6369	0.99285	1.02 (0.95- 1.09)	0.6295	0.93632
group6	Reference	0.99 (0.86- 1.13)	0.8414	0.99996	1.00 (0.93- 1.08)	0.9600	0.99860	1.01 (0.94- 1.09)	0.6974	0.93632
S:V70I	Reference	1.03 (0.89- 1.19)	0.6699	0.99996	1.02 (0.95- 1.10)	0.5570	0.98077	1.01 (0.94- 1.08)	0.8514	0.93632
group20	Reference	1.00 (0.88- 1.15)	0.9439	0.99996	1.00 (0.94- 1.07)	0.9986	0.99860	1.01 (0.94- 1.07)	0.8779	0.93632
S:R408S	Reference	1.01 (0.87- 1.18)	0.8801	0.99996	1.00 (0.91- 1.09)	0.9742	0.99860	1.01 (0.93- 1.10)	0.7979	0.93632
ORF1a:S3675T	Reference	0.97 (0.80- 1.16)	0.7068	0.99996	1.00 (0.90- 1.11)	0.9848	0.99860	1.01 (0.92- 1.11)	0.8491	0.93632
S:V70L	Reference	0.89 (0.62- 1.28)	0.5264	0.99996	1.06 (0.91- 1.23)	0.4816	0.98013	1.01 (0.86- 1.19)	0.9096	0.93632
S:H69L	Reference	0.61 (0.36- 1.03)	0.0640	0.98819	1.03 (0.88- 1.21)	0.6712	0.99285	1.01 (0.85- 1.20)	0.9075	0.93632
group7	Reference	0.95 (0.66- 1.36)	0.7696	0.99996	1.09 (0.90- 1.32)	0.3774	0.98013	1.01 (0.84- 1.21)	0.9374	0.93741
S:A21764-TACATG	Reference	1.04 (0.92- 1.18)	0.5275	0.99996	1.01 (0.95- 1.07)	0.7878	0.99285	1.00 (0.94- 1.07)	0.8937	0.93632
group26	Reference	1.06 (0.88- 1.29)	0.5289	0.99996	0.99 (0.92- 1.07)	0.7873	0.99285	0.99 (0.91- 1.07)	0.7439	0.93632
group4	Reference	1.06 (0.88- 1.28)	0.5447	0.99996	0.98 (0.91- 1.06)	0.5721	0.98077	0.97 (0.89- 1.05)	0.4805	0.88512
ORF1a:P1693R	Reference	1.05 (0.68- 1.63)	0.8134	0.99996	1.01 (0.81- 1.26)	0.9443	0.99860	0.97 (0.78- 1.21)	0.7922	0.93632
N:D343G	Reference	0.59 (0.31- 1.11)	0.1022	0.98819	0.87 (0.72- 1.06)	0.1683	0.98013	0.95 (0.77- 1.16)	0.5944	0.93632
N:S33F	Reference	1.34 (0.94- 1.92)	0.1098	0.98819	0.94 (0.73- 1.20)	0.6012	0.98381	0.86 (0.69- 1.08)	0.2069	0.75760
ORF1a:S2083I	Reference	1.07 (0.74- 1.53)	0.7251	0.99996	0.92 (0.80- 1.06)	0.2454	0.98013	0.80 (0.68- 0.93)	0.0046	0.07981
ORF1a:L2084I	Reference	0.90 (0.58- 1.40)	0.6480	0.99996	0.94 (0.81- 1.10)	0.4431	0.98013	0.69 (0.58- 0.82)	<.0001	0.00095

¹ Mutations with Pearson pairwise correlation >0.70 combined into groups for analysis:

- group 4: M:D3G, ORF1a:I3758V, ORF1a:K856R, S:A67V, S:G496S, S:N211I, S:N856K, S:R346K,
- S:S371P, S:T22204+GAGCCAGAA, S:T547K, S:T951 group 6: N:S413R, ORF1a:F3677L, ORF1a:G1307S, ORF1a:L3027F, ORF1a:S135R, ORF1a:T3090I, ORF1a:T842I, ORF1b:R1315C, ORF1b:T2163I, ORF3a:T223I, S:D405N, S:G142D, S:L24S, S:T19I, S:T376A, S:V213G group 7: S:L452Q, S:S704L
- group 11: S:E484A, S:N501Y, S:Q498R, S:S477N, S:T478K, S:Y505H
- group 12: ORF1a:L3201F, ORF6:D61L
- group 19: S:S371F, S:S373P, S:S375F
- group 20: S:K417N, S:N440K
- group 25: M:D3N, S:F486V, S:L452R
- group 26: ORF1a:A2710T, ORF1a:L3674F, S:G21986-GTGTTTATT, S:G22193-ATT, S:G446S, S:L981F
- group 45: S:A27S, S:C1254*
- group 64: N:P151S, ORF1a:F143L

² Adjusted risk ratios derived from Poisson regression models to assess the association of immunity status with each mutation group adjusting for age, sex, race/ethnicity, Charlson comorbidity index score, and month of SARS-CoV-2 infection.